Onglyza and Peripheral swelling - a phase IV clinical study of FDA data

Summary:

Peripheral swelling is reported as a side effect among people who take Onglyza (saxagliptin hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Metformin, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Peripheral swelling when taking Onglyza. It is created by eHealthMe based on reports of 8,520 people who have side effects when taking Onglyza from the FDA, and is updated regularly.

What is Onglyza?

Onglyza has active ingredients of saxagliptin hydrochloride. It is often used in diabetes. eHealthMe is studying from 8,638 Onglyza users. Check the latest studies of Onglyza.

What is Peripheral swelling?

Peripheral swelling is found to be associated with 2,182 drugs and 1,743 conditions by eHealthMe. Check the latest studies of Peripheral swelling.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

8,520 people reported to have side effects when taking Onglyza.
Among them, 93 people (1.09%) have Peripheral swelling.

Could Onglyza cause Peripheral swelling?

Among these 93 people:

How long have people been on Onglyza when they have Peripheral swelling? *

What is the gender of people who have Peripheral swelling when taking Onglyza? *

female: 79.52 %
male: 20.48 %

What is the age of people who have Peripheral swelling when taking Onglyza? *

What are other drugs people take besides Onglyza? *

What are other side effects people have besides Peripheral swelling? *

Fatigue (feeling of tiredness): 25 people, 26.88%
Nausea (feeling of having an urge to vomit): 23 people, 24.73%
Weight Decreased: 22 people, 23.66%
Oxygen Saturation Decreased: 19 people, 20.43%
High Blood Cholesterol: 18 people, 19.35%
Joint Pain: 17 people, 18.28%
Blood Pressure Fluctuation: 17 people, 18.28%
Headache (pain in head): 17 people, 18.28%
Fever: 17 people, 18.28%
Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 15 people, 16.13%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 47 people, 50.54%
High Blood Cholesterol: 22 people, 23.66%
High Blood Pressure: 7 people, 7.53%
Stress And Anxiety: 6 people, 6.45%
Multiple Myeloma (cancer of the plasma cells): 5 people, 5.38%
Joint Pain: 4 people, 4.30%
Vasculitis (inflammation of a blood vessel or blood vessels): 3 people, 3.23%
Felty's Syndrome (a combination of rheumatoid arthritis, an enlarged spleen, an abnormally low white blood count): 3 people, 3.23%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 3.23%
Cardiac Disorder: 3 people, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Onglyza and have Peripheral swelling?

- Check whether Peripheral swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Onglyza:

Onglyza (8,638 reports)

Browse all side effects of Onglyza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral swelling:

Peripheral swelling (2,182 drugs)

Browse all the conditions that are associated with Peripheral swelling:

Peripheral swelling (1,743 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on saxagliptin hydrochloride (the active ingredients of Onglyza) and Onglyza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.